Spyre Therapeutics (SYRE) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is SYRE's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Spyre Therapeutics, Inc. (SYRE) Presents at UBS Global Biopharma Conference 2026 Transcript…

WALTHAM, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate …

Announced positive topline induction data for SPY003 from Part A of the Phase 2 SKYLINE trial (“SKYLINE”), completing proof-of-concept for all three monotherapies in inflammatory bowel disease (“IBD”). SKYLINE Part B is …

WALTHAM, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology …

Spyre Therapeutics maintains a 'Strong Buy' rating, driven by promising IBD pipeline progress and robust cash reserves. SYRE's three monotherapy candidates—SPY001, SPY002, SPY003—show potential best-in-class efficacy for…

WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate …

WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate …

What happened Spyre Therapeutics, Inc. (NASDAQ: SYRE) Chief Legal Officer and Corporate Secretary Heidy King-Jones sold 28,933 shares on 2026-10-01. The Form 4 shows five sale blocks at weighted-average prices from $89.2…

WALTHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate …

Spyre Therapeutics, Inc. (NASDAQ: SYRE - Get Free Report)'s stock price gapped up prior to trading on Wednesday. The stock had previously closed at $84.72, but opened at $88.64. Spyre Therapeutics shares last traded at $…

Spyre Therapeutics (NASDAQ: SYRE - Get Free Report) and Gain Therapeutics (NASDAQ: GANX - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the s…

California State Teachers Retirement System grew its stake in shares of Spyre Therapeutics, Inc. (NASDAQ: SYRE) by 9,594.0% in a recent quarter, according to its most recent Form 13F filing with the Securities and Exchan…

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Spyre Therapeutics, Inc. (NASDAQ: SYRE) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commis…

Spyre Therapeutics, Inc. (SYRE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript…

SYRE's SPY003 posts positive phase II UC data, strengthening Spyre's multi-mechanism IBD strategy.…

SPY003 met its primary endpoint with a statistically significant reduction of 10.0 points (p…

WALTHAM, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate…

WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology…

Spyre Therapeutics (SYRE) reported earnings 30 days ago. What's next for the stock?…

Spyre's SPY072 shows activity in RA, but a smaller-than-expected benefit shifts its focus toward broader autoimmune uses and combinations.…

Spyre Therapeutics, Inc. (NASDAQ:SYRE) stock is trading lower on Wednesday after the company shared topline findings from the rheumatoid arthritis (RA) segment of its Phase 2 SKYWAY trial for SPY072.…

Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory endpoints (e.g., ACR50)…

SYRE expands into HS with SPY772, testing whether dual-pathway inhibition can strengthen outcomes in SKYLIGHT.…

Spyre has a broad clinical pipeline and cash runway, but elevated valuation makes upcoming readouts critical to its investment case.…

Spyre's 2026 clinical catalysts and positive ulcerative colitis data fuel momentum, but its lofty valuation raises the stakes for upcoming readouts.…
Kept in their own lane. A press release is the company talking, not reporting.
Expected by Feb 19. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

